Introduction
============

Colorectal cancer (CRC) is the third most diagnosed malignant tumor worldwide with over 600,000 related deaths a year.[@b1-ott-10-2199] In People's Republic of China, an estimated 376,300 new cases and 191,000 deaths from CRC occurred in 2015.[@b2-ott-10-2199] Understanding the risk factors for CRC may improve the development of pro-active precision medicine.

Metabolic syndrome (MetS) is characterized by a cluster of metabolic disturbances, including high blood pressure, obesity, atherogenic dyslipidemia, and impaired glucose metabolism.[@b3-ott-10-2199],[@b4-ott-10-2199] In the last recent decade, epidemiological and clinical studies have demonstrated a close link between MetS and an increased risk of CRC.[@b5-ott-10-2199],[@b6-ott-10-2199] However, the correlation between MetS and quantitative analysis of CRC outcome remained unclear.[@b7-ott-10-2199]--[@b10-ott-10-2199] One possible explanation might be related to the inter-individual and time-related differences in host systemic inflammatory status, and the quantification of an elevated inflammatory response which is associated with the progression and prognosis of CRC.[@b11-ott-10-2199]--[@b13-ott-10-2199] Furthermore, chronic low-grade inflammation leads to metabolic disturbances, which in turn lead to insulin resistance,[@b14-ott-10-2199] altered glucose and lipid metabolism triggering inflammation.[@b15-ott-10-2199]

Systemic inflammation can easily be assessed by means of peripheral blood markers such as serum white blood cells, neutrophils, lymphocytes and platelets, and acute-phase proteins. Platelet to lymphocyte ratio (PLR) has been reported to be associated with the prognosis of CRC.[@b16-ott-10-2199]--[@b18-ott-10-2199] Previous studies indicated that increased platelet counts were associated with MetS in adults.[@b19-ott-10-2199],[@b20-ott-10-2199] Akboga et al reported that increased PLR was significantly associated with MetS in a Turkish population.[@b21-ott-10-2199] Whether the presence of MetS, combined with the different levels of PLR, could improve the ability to predict prognosis of CRC remains unknown. As such, we aimed to evaluate the prognosis of the association of PLR with MetS in CRC patients.

Patients and methods
====================

Study patients
--------------

In this cross-sectional study, data were retrospectively collected from hospital records of 1,163 patients diagnosed with colorectal adenocarcinoma admitted to the First Affiliated Hospital of Wenzhou Medical University between April 2005 and April 2011. Exclusion criteria were as follows: clinical evidence of infection, hematological disease, enterobrosis, intestinal obstruction, neoadjuvant therapy, and patients with familial adenomatous polyposis syndrome. The study was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University and all study patients signed a written informed consent.

Diagnostic criteria of MetS
---------------------------

MetS is considered a cluster of metabolic disturbances.[@b3-ott-10-2199] In this study, we adopted the criteria proposed by the Chinese Diabetes Society in 2004.[@b22-ott-10-2199] MetS is defined as the presence of three or more of the following criteria: 1) body mass index (BMI) ≥25 kg/m^2^; 2) anti-hypertensive drug administration and (or) systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg; 3) triglycerides ≥1.7 mmol/L and (or) high-density lipoprotein (HDL) cholesterol \<0.9 mmol/L (male), \<1.0 mmol/L (female); and 4) fasting plasma glucose ≥6.1 mmol/L or 2 h postprandial glucose ≥7.8 mmol/L.

Clinical--pathological and laboratory data
------------------------------------------

Demographic information including date of birth, gender, age at CRC diagnosis, tobacco use, history of hypertension and diabetes, and family cancer history were recorded. Detailed clinical data such as body weight, height, and blood pressure were recorded within 1 week before surgery. Preoperative blood values including white blood cell, neutrophil, lymphocyte, monocyte and platelet counts were collected. PLR was calculated as the absolute platelet count divided by the absolute lymphocyte count. BMI was calculated as the weight in kg divided by the square of height in m (kg/m^2^).

Patients with CRC were treated primarily with surgical resection with adjuvant treatment according to the National Comprehensive Cancer Network guidelines. Tumor staging was performed according to the seventh edition of the American Joint Committee on Cancer staging manual.[@b23-ott-10-2199] In addition, information related to tumor location, histological differentiation, and vascular invasion was obtained from pathology reports.

Follow-up evaluation
--------------------

Follow-up evaluation was conducted every 3--6 months for the first 2 years after hospital discharge, every 6 months thereafter for a total of 5 years, and every year thereafter. Colonoscopy and computed tomography (CT) were performed at postoperative follow-up appointments in addition to blood analysis, including carcinoembryonic antigen (CEA) measurements. Tumor recurrence indicated by elevated CEA, abnormal findings on colonoscopy or CT scans, was defined as an earlier follow-up event. Information on death was obtained either from the patient's social security death index, outpatient medical records, or notifications from the relatives of the patients. The deadline of follow-up was August 1, 2016. Overall survival (OS) was defined as the time from the date of surgery to the date of death or the date of last follow-up. Disease-free survival (DFS) was defined as the time from the date of surgery to the time of recurrence or date of last follow-up.

Statistical analysis
--------------------

All continuous data were expressed as the mean ± standard deviation and compared using Student's *t*-test or Mann-- Whitney *U* test according to the data distribution. Categorical data were expressed in numbers (%) and compared by using the Chi-square test or Kruskal--Wallis test. Based on the optional cut-off values of our previous study,[@b16-ott-10-2199] the distribution of PLR, and the size of the study population with MetS, patients were stratified into three groups according to the two cut-off values (120, 220). The Kaplan--Meier survival function and log-rank tests were used to assess differences in OS and DFS. The prediction of different variables for the risks of CRC was calculated by Cox proportional hazard regression analyses. The risk effect-size estimates were expressed as hazard ratio (HR) with 95% confidence interval (CI). Variables with *P*≤0.1 from univariate Cox regression analysis were used in multivariate analysis by forward stepwise selection. All *P*-values were two-sided and a *P*-value \<0.05 was considered as statistically significant. Statistical analysis were performed using the SPSS statistical software package, version 19.0 (IBM Corporation, Armonk, NY, USA) and MedCalc version 13.0 (MedCalc Software, Mariakerke, Belgium).

Results
=======

Baseline characteristics
------------------------

Demographic and clinical characteristics are shown in [Table 1](#t1-ott-10-2199){ref-type="table"}. A total of 234 (20.1%) patients were identified to meet the criteria of MetS. The mean age of patients was 65 years, and the majority were male (60.2%). Six hundred and thirty-eight patients (54.9%) were diagnosed with rectal cancer. The majority of tumors were histologically well and moderately differentiated (74.6%). At initial diagnosis, 16.3% of the CRC patients presented with stage I, 38.2% with stage II, 38.0% with stage III, and 7.5% with stage IV.

The median preoperative PLR was 153. There were statistically significant differences between the groups with respect to total cholesterol, triglycerides, HDL, albumin, and uric acid (each parameter with *P*\<0.05). In addition, patients with PLR \>220 were significantly associated with higher incidence of stage IV and a tumor location at the right side. The tumors were also significantly associated with the clinical variable of vascular invasion (*P*\<0.05). There were no statistically significant differences in other clinical or pathological features. Although there is no difference in MetS between the PLR subgroup (*P*=0.719), further analyses showed a significant difference between the PLR subgroup, comparing the MetS subgroups stratified by the metabolic risk factors (*P*=0.016). PLR was also significantly higher in the MetS(+) group compared with MetS(−) (162.0±99.8 vs 150.6±68.3, *P*=0.039, [Table 2](#t2-ott-10-2199){ref-type="table"}), however, there was a graded tendency between increasing number of MetS components and PLR (146.3±66.2, 149.3±65.1, 153.8±72.1, 158.3±106.6, 169.5±84.9, *P*=0.150, respectively), as illustrated in [Figure 1](#f1-ott-10-2199){ref-type="fig"}.

Survival estimates according to PLR and MetS
--------------------------------------------

The mean follow-up time was 71.2 months. Kaplan--Meier analysis of OS and DFS demonstrated a progressively lower OS (*P*=0.002; [Figure 2A](#f2-ott-10-2199){ref-type="fig"}) and DFS (*P*=0.039; [Figure 2B](#f2-ott-10-2199){ref-type="fig"}) in elevated PLR groups. As shown in [Figure 3A](#f3-ott-10-2199){ref-type="fig"}, there was a trend of better OS for patients with MetS(−) compared to MetS(+), but the difference between the two survival curves was not statistically significant (*P*=0.233). Similar results were noticed for DFS (*P*=0.255, [Figure 3B](#f3-ott-10-2199){ref-type="fig"}).

Risk estimates of PLR and MetS
------------------------------

Cox proportional hazard models were used to identify variables associated with OS and DFS and the results are illustrated in [Table 3](#t3-ott-10-2199){ref-type="table"}. The patients with a PLR \>220 revealed a 59% increase in mortality risk and 43% increased risk for the recurrence of disease compared with patients with a PLR \<120 HR =1.594; 95% CI 1.227--2.070, *P*\<0.001 and HR =1.434; 95% CI 1.082--1.902, *P*=0.012, respectively). Gender, age, HDL, albumin, triglycerides, uric acid, tumor-node-metastasis (TNM) stage, tumor differentiation, the presence of vascular invasion, and CEA were also significantly associated with the risk of death based on univariate analysis (*P*\<0.05 for all measurements). In the multivariate analysis, PLR remained significantly associated with OS (HR =1.511; 95% CI 1.103--2.070, *P*=0.010). However, only HDL and TNM stage were independent predictors in multivariate Cox analysis for DFS (*P*\<0.05 for all measurements, [Table 3](#t3-ott-10-2199){ref-type="table"}).

Subgroup analyses associated with PLR and MetS
----------------------------------------------

In the MetS(+) subgroup, Kaplan--Meier analysis of OS showed significantly progressively worse OS with elevated PLR (*P*=0.004; [Figure 4A](#f4-ott-10-2199){ref-type="fig"}), compared with the MetS(−) subgroup (*P*=0.064), and PLR remained as an independent predictor for OS in the univariable and multivariable analysis (*P*=0.006, *P*=0.047, respectively, [Table 4](#t4-ott-10-2199){ref-type="table"}), but not for DFS (*P*=0.110, *P*=0.323, respectively). Considering the impact of different ranges of PLR, multivariate analysis showed that the subgroups with PLR values ≤220 were not associated with the prognosis after adjustment for MetS and PLR, even including other covariates. However, in the subgroup of patients with PLR values \>220, the difference between the two survival curves stratified by MetS was statistically significant in OS (*P*=0.043, [Figure 4B](#f4-ott-10-2199){ref-type="fig"}), and the coexistence of MetS was associated with a twofold increased risk of CRC mortality and recurrence (HR =2.0, HR =1.9 *P*\<0.05, respectively, [Table 5](#t5-ott-10-2199){ref-type="table"}).

Discussion
==========

The main findings of this study are as follows. PLR levels were significantly higher in CRC patients with MetS compared to patients not diagnosed with MetS. Also, no correlation was found with severity of MetS. We revealed that in the subgroup of patients with PLR values \>220, MetS was an independent predictor of the prognosis, and the presence of MetS was associated with a twofold increased risk of mortality and recurrence. To the best of our knowledge, there are no comparable reports describing the impact of both PLR values and MetS on the prognosis of patients with CRC.

MetS is defined as a cardiometabolic condition that increases the risk of type 2 diabetes mellitus, cardiovascular disease, and all-cause mortality including cancer.[@b24-ott-10-2199]--[@b26-ott-10-2199] Previous studies demonstrated that MetS was associated with an increased risk of mortality and recurrences in CRC patients.[@b9-ott-10-2199],[@b27-ott-10-2199] However, the mechanisms by which MetS affects the prognosis are not fully understood, although several hypotheses have been proposed, including inflammation and insulin resistance.[@b28-ott-10-2199]--[@b30-ott-10-2199] A low-grade inflammatory condition in MetS, termed as "metabolic inflammation" or "metaflammation", has been regarded as a vital factor that revealed a correlation with impaired demand and supply of oxygen, which results in hypoxia and subsequent inflammation.[@b31-ott-10-2199],[@b32-ott-10-2199] As such, an interaction between hypoxic and inflammatory signaling pathways and blood coagulation disorders have been related to CRC patients.[@b33-ott-10-2199]--[@b35-ott-10-2199]

In recent studies, PLR was considered a predictor of systemic inflammation and was correlated with the prognosis of CRC. Moreover, a higher PLR level was correlated with adverse postoperative survival in CRC patients.[@b16-ott-10-2199]--[@b18-ott-10-2199] In this study, we also found that there is an association of high PLR with right-sided colon cancer (RCC), but not left-sided colorectal cancer (LCRC) (*P*=0.001). Compared with LCRC, RCC had a delay in the diagnosis, due to the more subtle symptoms. To some extent, this leads to RCC having more active immune cells promoting immunogenicity and producing more inflammatory factors.[@b36-ott-10-2199] Several studies have indicated that patients with RCC have a worse prognosis compared to those with LCRC.[@b37-ott-10-2199],[@b38-ott-10-2199] This is consistent with the impact of PLR on the survival of CRC patients. In terms of stage distribution, it is well known that with the advanced TNM stage, malignant solid tumors had higher incidence of inducing a hypercoagulable state,[@b39-ott-10-2199],[@b40-ott-10-2199] which may gradually lead to thrombocytosis and high PLR. This can partly explain why PLRs are different in TNM stage distribution. Increased PLR levels were significantly associated with both the presence and severity of MetS in cardiology patients.[@b21-ott-10-2199] It has been shown that platelets are activated in case of MetS by linking inflammation and thrombosis.[@b41-ott-10-2199] Activated platelets also release pro-inflammatory mediators which interfere in the pathophysiology of MetS.[@b42-ott-10-2199] The latest meta-analysis reported that elevated platelet count and thrombocytosis prior to treatment, was related with a poor prognosis for patients with CRC.[@b43-ott-10-2199],[@b44-ott-10-2199] Lymphocytes play a vital role in cancer immune surveillance and suppress tumor maturation.[@b45-ott-10-2199] Based on the previous studies on PLR, peripheral platelets, lymphocytes or their ratio are indicators for the inflammatory process induced by tumor cells. A high level of platelets may promote tumor growth by increasing angiogenesis through the production of vascular endothelial growth factor (VEGF). It has been shown that the overexpression of VEGF was negatively associated with disease prognosis and metastasis in patients with various cancers, including CRC.[@b46-ott-10-2199]

There are some limitations to our study. First, this study has a retrospective cross-sectional design with single-center data and a relatively small number of MetS patients (n=234). Second, we chose the Chinese Diabetes Society (CDS) criteria to define MetS.[@b22-ott-10-2199] The CDS criteria used BMI rather than waist circumference as index to define "overweight" or "obese", because the application of the National Cholesterol Education Program-Adult Treatment Panel III criteria or the International Diabetes Federation criteria for Caucasians to East Asians would seriously underestimate the Chinese populations at risk of MetS.[@b47-ott-10-2199],[@b48-ott-10-2199] Third, all the CRC patients were enrolled between 2005 and late 2011, during the 7-year period, remarkable advances in surgical techniques and postoperative adjuvant treatment options might potentially have caused a bias. What is more, MetS is a reversible condition associated with a western lifestyle,[@b49-ott-10-2199] which could have underestimated the impact of MetS on CRC mortality.

In summary, we found that PLR is associated with MetS in CRC patients. PLR might be a useful marker to monitor an increased thrombotic status and inflammatory response in management of MetS, with respect to predicting the prognosis of CRC patients, and identifying novel treatment strategies. In daily clinical practice, much more attention should be paid to evaluating the presence and severity of MetS in CRC patients, especially with high PLR. Future studies are required to elucidate the relationship between PLR and MetS in CRC patients.
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![The graded relationship between increasing number of MetS components and PLR.\
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![Kaplan--Meier survival curves showing overall survival (**A**) and disease-free survival (**B**) stratified by PLR in CRC patients (cutoff values 120, 220, respectively).\
**Abbreviations:** CRC, colorectal cancer; PLR, platelet to lymphocyte ratio.](ott-10-2199Fig2){#f2-ott-10-2199}

![Kaplan--Meier survival curves showing overall survival (**A**) and disease-free survival (**B**) stratified by MetS in CRC patients.\
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![Kaplan--Meier survival curves showing overall survival stratified by PLR in CRC patients with MetS (**A**) and overall survival stratified by MetS in CRC patients with PLR \>220 (**B**).\
**Abbreviations:** CRC, colorectal cancer; MetS, metabolic syndrome; PLR, platelet to lymphocyte ratio.](ott-10-2199Fig4){#f4-ott-10-2199}

###### 

Characteristics of CRC patients treated with surgical resection according to PLR

  Characteristic                                   All patients N (%)   PLR ≤120 N=491   120\< PLR ≤220 N=465   PLR \>220 N=207   *P*-value
  ------------------------------------------------ -------------------- ---------------- ---------------------- ----------------- -----------
  Median PLR (mean ± SD)                           152.9±75.8           92.1±19.8        159.7±27.0             281.9±64.8        --
  **Demographic data**                                                                                                            
  Male, n (%)                                      700 (60.2%)          294 (59.9%)      288 (61.9%)            118 (57.0%)       0.475
  Female, n (%)                                    463 (39.8%)          197 (40.1%)      177 (38.1%)            89 (43.0%)        
  Age (mean ± SD)                                  65.2±12.2            66.1±11.6        64.6±12.1              64.5±13.4         0.103
  BMI (kg/m^2^) (mean ± SD)                        22.0±3.4             22.1±3.2         22.2±3.5               21.2±3.2          0.001
  DM, n (%)                                        112 (9.6%)           43 (8.8%)        47 (10.1%)             22 (10.6%)        0.674
  Hypertension, n (%)                              326 (28.0%)          135 (27.5%)      142 (30.5%)            49 (23.7%)        0.177
  Smoking, n (%)                                   308 (26.5%)          132 (26.9%)      123 (26.5%)            53 (25.6%)        0.936
  MetS, n (%)                                      234 (20.1%)          95 (19.3%)       99 (21.3%)             40 (19.3%)        0.719
   3[\*](#tfn1-ott-10-2199){ref-type="table-fn"}   156                  69 (44.2%)       68 (43.6%)             19 (12.2%)        0.016
   4[\*](#tfn1-ott-10-2199){ref-type="table-fn"}   78                   26 (33.3%)       31 (39.7%)             21 (26.9%)        
  **Laboratory data**                                                                                                             
  Fasting glucose (mmol/dL)                        6.1±2.2              5.9±2.3          6.1±2.1                6.3±2.0           0.144
  Total cholesterol (mmol/dL)                      4.5±1.1              4.6±0.9          4.5±1.1                4.2±1.2           0.001
  Triglycerides (mmol/dL)                          1.5±1.0              1.5±0.9          1.5±1.2                1.3±0.8           0.007
  HDL (mmol/dL)                                    1.1±0.3              1.2±0.3          1.1±0.3                1.1±0.3           0.001
  LDL (mmol/dL)                                    2.7±0.9              2.7±0.8          2.8±0.9                2.6±1.0           0.117
  Albumin (g/L)                                    40.6±5.4             41.9±4.5         40.5±5.4               37.9±6.2          0.001
  Creatinine (μmol/L)                              67.6±32.0            67.7±27.5        69.2±35.0              64.0±34.4         0.151
  Uric acid (mmol/L)                               297.8±94.9           309.4±87.9       300.1±97.1             264.8±98.7        0.001
  CEA (ng/mL)                                      30.5±153.4           28.5±152.9       29.5±150.9             37.9±160.8        0.765
  **Pathological data**                                                                                                           
  Location                                                                                                                        0.001
   Right side, n (%)                               172 (14.8%)          49 (10.0%)       71 (15.3%)             52 (25.1%)        
   Sigmoid, n (%)                                  200 (17.2%)          86 (17.5%)       80 (17.2%)             34 (16.45%)       
   Rectal, n (%)                                   638 (54.9%)          305 (62.1%)      254 (54.6%)            79 (38.2%)        
  TNM staging                                                                                                                     0.002
   Stage I, n (%)                                  189 (16.3%)          100 (20.4%)      69 (14.8%)             20 (9.7%)         
   Stage II, n (%)                                 444 (38.2%)          174 (35.4%)      186 (40.0%)            84 (40.6%)        
   Stage III, n (%)                                442 (38.0%)          190 (38.7%)      174 (37.4%)            78 (37.7%)        
   Stage IV, n (%)                                 88 (7.5%)            27 (5.5%)        36 (7.7%)              25 (12.1%)        
  Tumor differentiation                                                                                                           
   Well/moderate, n (%)                            868 (74.6%)          372 (75.8%)      350 (75.3%)            146 (70.5%)       0.321
   Poor, n (%)                                     295 (25.4%)          119 (24.2%)      115 (24.7%)            61 (29.5%)        
  Vascular invasion, n (%)                         166 (14.3%)          51 (10.4%)       81 (17.4%)             34 (16.4%)        0.005
  **Treatment**                                                                                                                   0.591
  Local treatment, n (%)                           147 (12.6%)          56 (11.4%)       65 (14.0%)             26 (12.6%)        
  Op alone, n (%)                                  290 (24.9%)          116 (23.6%)      121 (26.0%)            53 (25.6%)        
  Op + CTx/RTx, n (%)                              726 (62.4%)          319 (65.0%)      279 (60.0%)            128 (61.8%)       

**Note:**

Number of metabolic risk factors.

**Abbreviations:** BMI, body mass index; CEA, carcinoembryonic antigen; CRC, colorectal cancer; CTx, chemotherapy; DM, diabetes mellitus; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MetS, metabolic syndrome; Op, operation; PLR, platelet to lymphocyte ratio; RTx, radiotherapy; SD, standard deviation; TNM, tumor-node-metastasis.

###### 

Baseline characteristics of CRC patients stratified by MetS

  Variables                          MetS(−) (n=929)   MetS(+) (n=234)   *P*-value
  ---------------------------------- ----------------- ----------------- -----------
  **Demographic data**                                                   
  Male gender, n (%)                 571 (61.5%)       129 (55.15%)      0.077
  Age (years)                        64.8±12.5         67.0±10.5         0.007
  BMI (kg/m^2^)                      21.3±2.9          24.6±3.7          \<0.001
  DM, n (%)                          70 (7.5%)         42 (17.9%)        \<0.001
  Hypertension, n (%)                219 (23.6%)       107 (45.7%)       \<0.001
  Smoking, n (%)                     250 (26.9%)       58 (24.9%)        0.527
  **Preoperative laboratory data**                                       
  PLR                                150.6±68.3        162.0±99.8        0.039
  Fasting glucose (mmol/dL)          5.8±1.7           7.4±3.2           \<0.001
  Albumin (g/L)                      40.7±5.2          40.5±5.9          0.593
  Total cholesterol (mmol/dL)        4.5±1.0           4.6±1.2           0.169
  Triglycerides (mmol/dL)            1.3±0.8           2.0±1.3           \<0.001
  HDL (mmol/dL)                      1.2±0.3           1.0±0.3           \<0.001
  LDL (mmol/dL)                      2.7±0.9           2.7±0.9           0.844
  Creatinine (μmol/L)                66.7±26.4         71.3±48.0         0.163
  Uric acid (mmol/L)                 294.5±92.8        310.9±101.7       0.018
  CEA (ng/mL)                        31.9±160.4        25.0±121.4        0.553

**Abbreviations:** BMI, body mass index; CEA, carcinoembryonic antigen; CRC, colorectal cancer; DM, diabetes mellitus; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MetS, metabolic syndrome; PLR, platelet to lymphocyte ratio.

###### 

Cox proportional hazard regression models of risk factors associated with prognosis among CRC patients

                            Overall survival   Disease-free survival                                                                                                             
  ------------------------- ------------------ ----------------------- --------- -------- --------------- --------- ------- --------------- --------- ---------- --------------- ---------
  Gender (male vs female)   1.365              1.113--1.673            0.003     1.447    1.136--1.844    0.003     1.336   1.072--1.665    0.010     1.384      1.096--1.747    0.006
  Age                       1.014              1.005--1.022            \<0.001   1.008    1.003--1.021    0.068     1.001   0.993--1.010    0.747                                
  Diabetes                  0.997              0.847--1.174            0.974                                        0.990   0.830--1.182    0.915                                
  Hypertension              0.860              0.697--1.060            0.158                                        0.860   0.697--1.060    0.158                                
  MetS                      0.932              0.830--1.047            0.235                                        0.929   0.818--1.055    0.257                                
  BMI (continuous)          0.974              0.945--1.003            0.080     0.986    0.954--1.019    0.391     1.000   0.969--1.032    0.990                                
  PLR (continuous)          1.001              1.000--1.003            0.014     0.996    0.993--1.000    0.043     1.001   1.000--1.002    0.117                                
   PLR ≤120                 1.000              --                      --        1.000    --              --        1.000   --              --        1.000 --                   --
   120\< PLR ≤220           1.247              1.002--1.552            0.048     1.445    1.029--2.030    0.034     1.089   0.860--1.379    0.478     1.077      0.844--1.374    0.551
   PLR \>220                1.594              1.227--2.070            \<0.001   2.374    1.127--5.002    0.023     1.434   1.082--1.902    0.012     1.110      0.809--1.523    0.519
  Total cholesterol         0.908              0.823--1.002            0.055     1.064    0.950--1.191    0.283     0.947   0.852--1.053    0.316                                
  Triglycerides             0.887              0.790--0.996            0.042     0.948    0.841--1.068    0.378     0.976   0.875--1.089    0.663                                
  HDL                       0.574              0.412--0.798            \<0.001   0.876    0.588--1.306    0.516     0.534   0.371--0.767    0.001     0.668      0.451--0.989    0.044
  LDL                       0.934              0.811--1.076            0.347                                        0.921   0.790--1.073    0.291                                
  Albumin                   0.958              0.942--0.973            \<0.001   0.964    0.942--0.986    0.002     0.970   0.952--0.988    0.001     0.978      0.957--0.999    0.044
  Creatinine                1.001              0.998--1.003            0.652                                        1.001   0.998--1.004    0.428                                
  Uric acid                 0.999              0.998--1.000            0.037     0.999    0.998--1.001    0.347     0.999   0.998--1.000    0.104                                
  TNM staging                                                                                                                                                                    
   Stage I                  1.000              --                      --        1.000    --              --        1.000   --              --        1.000 --                   --
   Stage II                 0.983              0.675--1.431            0.927     0.840    0.565--1.249    0.390     1.022   0.707--1.478    0.908     0.956      0.650--1.406    0.819
   Stage III                2.794              1.983--3.938            \<0.001   2.321    1.602--3.364    \<0.001   2.920   2.082--4.095    \<0.001   2.780      1.936--3.993    \<0.001
   Stage IV                 15.369             10.407--22.699          \<0.001   12.655   8.252--19.406   \<0.001   8.007   1.933--33.165   0.004     7.300      1.746--30.523   \<0.001
  Differentiation           0.676              0.548--0.833            \<0.001   0.917    0.728--1.156    0.464     0.664   0.528--0.834    \<0.001   0.882      0.690--1.128    0.316
  Vascular invasion         0.532              0.420--0.674            \<0.001   0.777    0.587--1.012    0.061     0.589   0.450--0.771    \<0.001   0.844      0.630--1.130    0.255
  CEA                       1.001              1.001--1.002            \<0.001   1.000    1.000--1.001    0.089     1.001   1.000--1.001    0.272                                

**Abbreviations:** BMI, body mass index; CEA, carcinoembryonic antigen; CI, confidence interval; CRC, colorectal cancer; HDL, high-density lipoprotein; HR, hazard ratio; LDL, low-density lipoprotein; MetS, metabolic syndrome; PLR, platelet to lymphocyte ratio; TNM, tumor-node-metastasis.

###### 

Cox proportional hazard regression analysis of prognosis stratified by MetS

  MetS             PLR                                                 Overall survival   Disease-free survival                                                                                                
  ---------------- --------------------------------------------------- ------------------ ----------------------- ------- -------------- ------- ------- -------------- ------- ------- -------------- ------- -------
  MetS(+) group    PLR[\*\*](#tfn6-ott-10-2199){ref-type="table-fn"}   --                 --                      0.006                          0.047                          0.110                          0.323
  PLR ≤120         1.000                                               --                 --                      1.000   --             --      1.000   --             --      1.000   --             --      
  120\< PLR ≤220   1.452                                               0.896--2.354       0.130                   1.241   0.763--2.018   0.385   1.075   0.645--1.790   0.782   0.946   0.564--1.588   0.834   
  PLR \>220        2.471                                               1.422--4.293       0.001                   1.997   1.143--3.489   0.015   1.843   1.012--3.355   0.046   1.468   0.801--2.689   0.214   
  MetS(−) group    PLR[\*\*](#tfn6-ott-10-2199){ref-type="table-fn"}                                              0.066                          0.018                          0.185                          0.111
  PLR ≤120         1.000                                               --                 --                      1.000   --             --      1.000   --             --      1.000   --             --      
  120\< PLR ≤220   1.194                                               0.934--1.526       0.158                   1.253   0.980--1.603   0.072   1.092   0.837--1.425   0.517   1.139   0.873--1.487   0.338   
  PLR \>220        1.415                                               1.050--1.906       0.023                   1.525   1.131--2.058   0.006   1.349   0.979--1.857   0.067   1.410   1.022--1.946   0.036   

**Notes:**

Adjusted for all covariates including age, gender, PLR, and TNM staging.

Categorical variable.

**Abbreviations:** CI, confidence interval; HR, hazard ratio; MetS, metabolic syndrome; PLR, platelet to lymphocyte ratio; TNM, tumor-node-metastasis.

###### 

Cox proportional hazard regression analysis of the prognosis of the subgroups of PLR

  PLR        Overall survival   Disease-free survival                                                                                                
  ---------- ------------------ ----------------------- ------- ------- -------------- ------- ------- -------------- ------- ------- -------------- -------
  \<120                                                                                                                                              
   MetS      1.072              0.619--1.408            0.742   1.052   0.695--1.592   0.810   1.105   0.734--1.664   0.633   1.298   0.857--1.966   0.218
   PLR       1.003              0.989--1.005            0.476   0.996   0.988--1.004   0.298   1.005   0.987--1.013   0.227   0.994   0.986--1.002   0.131
  120--220                                                                                                                                           
   MetS      1.148              0.611--1.240            0.443   0.908   0.636--1.295   0.593   0.921   0.614--1.380   0.690   0.895   0.595--1.346   0.594
   PLR       1.001              0.995--1.006            0.833   1.000   0.994--1.005   0.989   1.002   0.996--1.008   0.510   1.001   0.995--1.007   0.705
  \>220                                                                                                                                              
   MetS      2.016              1.233--3.289            0.005   1.704   1.028--2.825   0.039   1.887   1.081--3.289   0.025   1.779   1.008--3.135   0.047
   PLR       1.005              1.000--1.009            0.031   1.004   1.000--1.008   0.051   1.005   1.000--1.010   0.044   1.005   1.000--1.010   0.058

**Notes:**

Adjusted for MetS and PLR.

Adjusted for covariates including age, gender, MetS, PLR, and TNM staging.

**Abbreviations:** CI, confidence interval; HR, hazard ratio; MetS, metabolic syndrome; PLR, platelet to lymphocyte ratio; TNM, tumor-node-metastasis.

[^1]: These authors contributed equally to this work
